GB00BMVP7Y09 - Common Stock

**RPRX** gets a fundamental rating of **5** out of 10. The analysis compared the fundamentals against 205 industry peers in the **Pharmaceuticals** industry. Both the profitability and the financial health of **RPRX** get a neutral evaluation. Nothing too spectacular is happening here. **RPRX** is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make **RPRX** suitable for value investing!

In the past year **RPRX** was profitable.

In the past 5 years **RPRX** always reported a positive cash flow from operatings.

Measured over the past 3 years, the **Average Return On Invested Capital** for **RPRX** is significantly below the industry average of **16.81%**.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 1.16% | ||

ROE | 3% | ||

ROIC | 5.08% |

ROA(3y)2.29%

ROA(5y)7.57%

ROE(3y)7.25%

ROE(5y)18.18%

ROIC(3y)6.51%

ROIC(5y)9.32%

With an excellent **Profit Margin** value of **7.93%**, **RPRX** belongs to the best of the industry, outperforming **87.80%** of the companies in the same industry.

In the last couple of years the **Profit Margin** of **RPRX** has declined.

With an excellent **Operating Margin** value of **43.55%**, **RPRX** belongs to the best of the industry, outperforming **98.54%** of the companies in the same industry.

In the last couple of years the **Operating Margin** of **RPRX** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 43.55% | ||

PM (TTM) | 7.93% | ||

GM | N/A |

OM growth 3Y-34.17%

OM growth 5Y-6.85%

PM growth 3Y-75.46%

PM growth 5Y-52.08%

GM growth 3YN/A

GM growth 5YN/A

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), **RPRX** is destroying value.

Compared to 1 year ago, **RPRX** has more shares outstanding

The Debt to FCF ratio of **RPRX** is **4.31**, which is a neutral value as it means it would take **RPRX**, **4.31** years of fcf income to pay off all of its debts.

A Debt/Equity ratio of **1.00** indicates that **RPRX** is somewhat dependend on debt financing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1 | ||

Debt/FCF | 4.31 | ||

Altman-Z | 1.67 |

ROIC/WACC0.62

WACC8.16%

With an excellent **Current ratio** value of **13.51**, **RPRX** belongs to the best of the industry, outperforming **87.32%** of the companies in the same industry.

Looking at the **Quick ratio**, with a value of **13.51**, **RPRX** belongs to the top of the industry, outperforming **87.32%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 13.51 | ||

Quick Ratio | 13.51 |

The **Earnings Per Share** has grown by an impressive **64.60%** over the past year.

The earnings per share for **RPRX** have been decreasing by **-45.24%** on average. This is quite bad

The **Revenue** has been growing slightly by **3.43%** in the past year.

EPS 1Y (TTM)64.6%

EPS 3Y-70.61%

EPS 5Y-45.24%

EPS growth Q2Q9.72%

Revenue 1Y (TTM)3.43%

Revenue growth 3Y7.23%

Revenue growth 5Y6.96%

Revenue growth Q2Q-6.49%

Based on estimates for the next years, **RPRX** will show a small growth in **Earnings Per Share**. The EPS will grow by **5.26%** on average per year.

The **Revenue** is expected to grow by **5.66%** on average over the next years.

EPS Next Y14.92%

EPS Next 2Y4.35%

EPS Next 3Y6.72%

EPS Next 5Y5.26%

Revenue Next Year5.33%

Revenue Next 2Y-0.16%

Revenue Next 3Y4.25%

Revenue Next 5Y5.66%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

Based on the **Price/Earnings** ratio of **5.66**, the valuation of **RPRX** can be described as very cheap.

Compared to an average S&P500 **Price/Earnings** ratio of **24.46**, **RPRX** is valued rather cheaply.

With a **Price/Forward Earnings** ratio of **6.78**, the valuation of **RPRX** can be described as very cheap.

92.68% of the companies in the same industry are more expensive than **RPRX**, based on the **Price/Forward Earnings** ratio.

The average S&P500 **Price/Forward Earnings** ratio is at **19.59**. **RPRX** is valued rather cheaply when compared to this.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 5.66 | ||

Fwd PE | 6.78 |

Based on the **Price/Free Cash Flow** ratio, **RPRX** is valued cheaper than 89.76% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 11.47 | ||

EV/EBITDA | N/A |

PEG (NY)0.38

PEG (5Y)N/A

EPS Next 2Y4.35%

EPS Next 3Y6.72%

With a **Yearly Dividend Yield** of **2.94%**, **RPRX** has a reasonable but not impressive dividend return.

Compared to an average S&P500 **Dividend Yield** of **2.63**, **RPRX** has a dividend comparable with the average S&P500 company.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 2.94% |

Dividend Growth(5Y)N/A

Div Incr Years2

Div Non Decr Years2

DP191.54%

EPS Next 2Y4.35%

EPS Next 3Y6.72%

**ROYALTY PHARMA PLC- CL A**

NASDAQ:RPRX (11/28/2023, 7:26:44 PM)

After market: 27.09 0 (0%)**27.09**

**-0.05 (-0.18%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-08 2023-11-08/bmo

Earnings (Next)02-13 2024-02-13/amc

Inst Owners49.87%

Inst Owner Change-1.08%

Ins Owners0.18%

Ins Owner Change15.13%

Market Cap16.30B

Analysts84.62

Price Target49.64 (83.24%)

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 2.94% |

Dividend Growth(5Y)N/A

DP191.54%

Div Incr Years2

Div Non Decr Years2

Ex-Date11-16 2023-11-16 (0.2)

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)2.19%

Min EPS beat(2)1.92%

Max EPS beat(2)2.45%

EPS beat(4)4

Avg EPS beat(4)7.86%

Min EPS beat(4)1.92%

Max EPS beat(4)23.19%

Revenue beat(2)0

Avg Revenue beat(2)-8.29%

Min Revenue beat(2)-14.92%

Max Revenue beat(2)-1.67%

Revenue beat(4)0

Avg Revenue beat(4)-19.92%

Min Revenue beat(4)-41.7%

Max Revenue beat(4)-1.67%

PT rev (1m)0.69%

PT rev (3m)-1.2%

EPS NQ rev (1m)1.03%

EPS NQ rev (3m)0.81%

EPS NY rev (1m)0%

EPS NY rev (3m)1.32%

Revenue NQ rev (1m)6.07%

Revenue NQ rev (3m)6.84%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-0.27%

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 5.66 | ||

Fwd PE | 6.78 | ||

P/S | 7.01 | ||

P/FCF | 11.47 | ||

P/OCF | 5.85 | ||

P/B | 2.66 | ||

P/tB | 2.66 | ||

EV/EBITDA | N/A |

EPS(TTM)4.79

EY17.68%

EPS(NY)4

Fwd EY14.75%

FCF(TTM)2.36

FCFY8.72%

OCF(TTM)4.63

OCFY17.08%

SpS3.86

BVpS10.2

TBVpS10.2

PEG (NY)0.38

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 1.16% | ||

ROE | 3% | ||

ROCE | 6.44% | ||

ROIC | 5.08% | ||

ROICexc | 5.69% | ||

ROICexgc | 5.69% | ||

OM | 43.55% | ||

PM (TTM) | 7.93% | ||

GM | N/A | ||

FCFM | 61.17% |

ROA(3y)2.29%

ROA(5y)7.57%

ROE(3y)7.25%

ROE(5y)18.18%

ROIC(3y)6.51%

ROIC(5y)9.32%

ROICexc(3y)7.78%

ROICexc(5y)10.89%

ROICexgc(3y)7.79%

ROICexgc(5y)10.94%

ROCE(3y)8.24%

ROCE(5y)11.8%

ROICexcg growth 3Y-33.06%

ROICexcg growth 5YN/A

ROICexc growth 3Y-32.95%

ROICexc growth 5YN/A

OM growth 3Y-34.17%

OM growth 5Y-6.85%

PM growth 3Y-75.46%

PM growth 5Y-52.08%

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.15

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 1 | ||

Debt/FCF | 4.31 | ||

Debt/EBITDA | N/A | ||

Cap/Depr | N/A | ||

Cap/Sales | 58.67% | ||

Interest Coverage | -6.08 | ||

Cash Conversion | N/A | ||

Profit Quality | 770.99% | ||

Current Ratio | 13.51 | ||

Quick Ratio | 13.51 | ||

Altman-Z | 1.67 |

F-Score5

WACC8.16%

ROIC/WACC0.62

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)92.13%

Cap/Sales(5y)77.26%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

Growth

EPS 1Y (TTM)64.6%

EPS 3Y-70.61%

EPS 5Y-45.24%

EPS growth Q2Q9.72%

EPS Next Y14.92%

EPS Next 2Y4.35%

EPS Next 3Y6.72%

EPS Next 5Y5.26%

Revenue 1Y (TTM)3.43%

Revenue growth 3Y7.23%

Revenue growth 5Y6.96%

Revenue growth Q2Q-6.49%

Revenue Next Year5.33%

Revenue Next 2Y-0.16%

Revenue Next 3Y4.25%

Revenue Next 5Y5.66%

EBIT growth 1Y7.34%

EBIT growth 3Y-29.4%

EBIT growth 5Y-0.36%

EBIT Next Year5.68%

EBIT Next 3Y3.66%

EBIT Next 5Y3.75%

FCF growth 1Y294.3%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y33.06%

OCF growth 3Y8.75%

OCF growth 5Y8.62%